Primary Site >> Colorectal Cancer

Gene >> ALPK1

  • 1988
  • 1989
  • 1990
  • 1991
  • 1992
  • 1993
  • 1994
  • 1995
  • 1997
  • 1998
  • 2000
  • 2016
Ref: [Adoptive immunotherapy of malignant disease using LAK cells].
PMID: 3260466
Ref: A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma.
PMID: 2670212
Ref: [Potent effects of the prostaglandin synthesis inhibitor indomethacin on the cellular immune response in gastrointestinal cancer patients].
PMID: 2778378
Ref: The clinical significance of interleukin-2.
PMID: 2092277
Ref: Swainsonine, an inhibitor of glycoprotein processing, enhances cytotoxicity of large granular lymphocytes.
PMID: 2108487
Ref: Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
PMID: 2123477
Ref: [Immunotherapy and quality of life].
PMID: 2344201
Ref: The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype.
PMID: 1706327
Ref: Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells.
PMID: 1787836
Ref: [Effect of UFT by oral administration using a murine hepatic metastasis model].
PMID: 1888182
Ref: [Splenic or hepatic arterial injections of interleukin-2 with chemotherapeutic agents for hepatic metastases].
PMID: 1944193
Ref: CEA and NCA expressed by colon carcinoma cells affect their interaction with and lysability by activated lymphocytes.
PMID: 1431336
Ref: [Significance of antitumor effects and immunological response on endogenously induced LAK therapy for primary or metastatic liver tumor].
PMID: 1530292
Ref: Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer.
PMID: 1622739
Ref: Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells.
PMID: 8428794
Ref: [Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients].
PMID: 7720497
Ref: CEA expression of colorectal adenocarcinomas is correlated with their resistance against LAK-cell lysis.
PMID: 8168994
Ref: [Autologous bone marrow transplantation in intestinal carcinoma].
PMID: 7762252
Ref: Effect of essential fatty acids on natural cytotoxicity in patients with colorectal cancer.
PMID: 7781792
Ref: The influence of the local environment on tissue architecture of colorectal carcinoma (CRC) cell aggregates and its consequence for tumour attack by lymphocytes in vitro and in vivo.
PMID: 8652264
Ref: Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes.
PMID: 9042431
Ref: Modulations of the effector function and cytokine production of human lymphocytes by secreted factors derived from colorectal-carcinoma cells.
PMID: 9212235
Ref: Preclinical studies with prothymosin alpha1 on mononuclear cells from tumor patients.
PMID: 9637344
Ref: IL-2-Activated Killer Cells and Native Cytokines in Treatment of Patients with Advanced Cancer.
PMID: 12687071
Ref: Effects of thymic peptides, in vitro, on the impaired immunocytotoxicity of peripheral blood mononuclear cells from tumor patients.
PMID: 21533400
Ref: Low molecular thymic peptides improve the deficient immunocytotoxicity of mononuclear cells from tumor patients in vitro.
PMID: 21590251
Ref: Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro.
PMID: 9499461
Ref: Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells.
PMID: 11006006
Ref: Down-regulated and Commonly mutated ALPK1 in Lung and Colorectal Cancers.
PMID: 27283888